Skip to main content

Edarbyclor Side Effects

Generic name: azilsartan medoxomil / chlorthalidone

Medically reviewed by Last updated on Aug 15, 2022.

Note: This document contains side effect information about azilsartan medoxomil / chlorthalidone. Some of the dosage forms listed on this page may not apply to the brand name Edarbyclor.

For the Consumer

Applies to azilsartan medoxomil/chlorthalidone: oral tablet


Oral route (Tablet)

Discontinue use of azilsartan medoxomil / chlorthalidone as quickly as possible if pregnancy is detected, as drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Side effects requiring immediate medical attention

Along with its needed effects, azilsartan medoxomil / chlorthalidone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking azilsartan medoxomil / chlorthalidone:

Less common

  • Blurred vision
  • confusion
  • convulsions
  • decreased urine
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • dry mouth
  • fainting
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • muscle pain or cramps
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • shortness of breath
  • sweating
  • unusual tiredness or weakness

Incidence not known

  • Ankle, knee, or great toe joint pain
  • joint stiffness or swelling
  • lower back, side, or stomach pain
  • swelling of the feet or lower legs

Side effects not requiring immediate medical attention

Some side effects of azilsartan medoxomil / chlorthalidone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Dizziness


  • Cough
  • diarrhea
  • lack or loss of strength
  • muscle spasm

Incidence not known

  • Headache
  • loss of appetite
  • rash
  • stomach cramps

For Healthcare Professionals

Applies to azilsartan medoxomil / chlorthalidone: oral tablet


The most common side effects were dizziness and fatigue.[Ref]

Nervous system

Common (1% to 10%): Dizziness

Uncommon (0.1% to 1%): Syncope

Postmarketing reports: Loss of consciousness


Common (1% to 10%): Dizziness

Frequency not reported: Dizziness postural


Common (1% to 10%): Dizziness

Frequency not reported: Headache[Ref]


Common (1% to 10%): Fatigue


Uncommon (0.1% to 1%): Fatigue

Frequency not reported: Asthenia


Common (1% to 10%): Fatigue[Ref]


Common (1% to 10%): Consecutive creatinine increases of 50% or greater from baseline and greater than the upper limit of normal


Uncommon (0.1% to 1%): Consecutive creatinine increases of 50% or greater from baseline and greater than the upper limit of normal


Uncommon (0.1% to 1%): Consecutive creatinine increases of 50% or greater from baseline and greater than the upper limit of normal[Ref]


Postmarketing reports: Nausea


Frequency not reported: Diarrhea, nausea


Frequency not reported: Gastrointestinal upset[Ref]


Common (1% to 10%): Hypotension[Ref]


Postmarketing reports: Rash, pruritus, angioedema


Frequency not reported: Rash[Ref]



Frequency not reported: Cholesterol elevated[Ref]


Frequency not reported: BUN increased


Frequency not reported: Uric acid elevated[Ref]



Frequency not reported: Muscle spasm[Ref]



Frequency not reported: Cough[Ref]


1. "Product Information. Edarbyclor (azilsartan-chlorthalidone)." Takeda Pharmaceuticals America (2012):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.